OSR Holdings, Inc. is a global healthcare company, dedicated to advancing healthcare outcomes and improving the quality of life for people and their families. The Company is focused on building and developing a portfolio of transformative therapies and healthcare solutions. The Company's operating businesses (through its three wholly owned subsidiaries) include developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases and neurovascular intervention medical device and systems distribution in Korea. The Company’s subsidiary, Vaximm’s flagship asset, VXM01, is a late clinical-stage (NCT037500701) immuno-oncology candidate for glioblastoma. Vaximm has three clinical and pre-clinical drug candidates targeting diseases ranging from glioblastoma to gastrointestinal stromal tumor to ocular diseases. The Company has operations in Europe and South Korea.